果酱视频

Metformin HCL prices in the Chinese pharmaceutical market remained on a downward trend in the first half of the month of August ****, following the considerable drops registered in July. This continued decrease in price was mainly caused by high inventory holdings as the suppliers lowered prices to liquidate the surplus. Although the core downstream demand in pharmaceuticals and healthcare sectors was stable, the oversupply position continued to be the prevailing condition affecting market sentiment and pricing strategies of Metformin HCL.

Metformin HCL (USP, FDA) FOB Shanghai rates reached USD ****/MT in July, falling by ** compared to the previous month. This sharp decrease was a combination of weak demand and intense inventory clearance. After the shutdowns of plants in June, production has resumed, and market availability of Metformin HCL has risen significantly. Adverse monsoons and floods in the region also...